Colon Cancer: Causes, Symptoms, Treatment

Colon cancer is a malignant disease originating in the large intestine (the colon), usually beginning as benign cell clumps called adenomatous polyps. It represents a critical global health burden and stands as a leading cause of cancer-related mortality worldwide.

In the UK, bowel cancer (including colon and rectal cancer) is the 4th most common cancer overall, but the second biggest cancer killer—accounting for roughly 11% of all cancer deaths. Every year brings over 49,300 new diagnoses and approximately 17,900 related deaths.

In 2026, colorectal oncology focuses on refining non-invasive home screening, comprehensive next-generation genomic sequencing of tumours, and introducing targeted immunotherapy combinations for specific genetic subtypes to prevent advanced progression.

1. Incidence and Statistics

The epidemiology of colon cancer underscores its widespread impact across demographic groups:

• Gendere: Annual incidence shows a slight male predominance, with roughly 26,800 new cases in men and 21,400 in women each year in the UK.

• Age Distribution: It is heavily associated with ageing. More than 90% of cases occur in individuals aged 50 and over, with over 40% diagnosed in those aged 75 and older.

• Socioeconomic Impact: Incidence and mortality rates are higher in deprived communities, frequently correlating with regional dietary patterns, higher obesity rates, and lower screening uptake.

2. Types and Pathological Classifications

Clinicians categorise cancers of the large bowel based on cellular origin and genomic landscape, which dictates surgical and systemic treatment pathways:

• Adenocarcinomas: Accounting for over 95% of cases, these develop in the mucus-producing cells lining the large intestine. Main subtypes include mucinous and signet ring cell adenocarcinoma, the latter being more aggressive.

• Gastrointestinal Stromal Tumours (GISTs) & Neuroendocrine Tumours (NETs): Rarer malignancies starting in the structural walls of the GI tract or specialized neuroendocrine cellular networks.

• MSI-H vs. MSS Status: Tumours are critically divided by DNA mismatch repair status. Microsatellite Instability-High (MSI-H) tumours respond exceptionally well to immunotherapies, whereas Microsatellite Stable (MSS) tumours require distinct systemic strategies.

3. Causes and Risk Factors (Modifiable vs. Genetic)

The risk profile is heavily influenced by Western lifestyle factors alongside well-defined inherited genetic syndromes.

4. Typical Symptoms and Red Flag Signs

In its earliest stages, colon cancer can be entirely asymptomatic, making home-based Faecal Immunochemical Testing (FIT) for eligible adults aged 50–74 vital. As the tumour grows and alters bowel function, clear red flag signs emerge:

• Persistent Change in Bowel Habits: A lasting shift toward looser stools, diarrhoea, or increased frequency lasting longer than three weeks.

• Rectal Bleeding: Finding blood in the stool or bleeding from the rectum without an obvious localised cause like haemorrhoids.

• Abdominal Pain or Mass: Persistent discomfort, bloating, cramping, or a physical lump detectable by a doctor in the abdomen.

5. Atypical and Systemic Signs

Some symptoms do not immediately point to the digestive system, appearing instead as generalised complaints:

• Unexplained Iron-Deficiency Anaemia: Microscopic, slow bleeding from a proximal colon tumour can deplete iron reserves, causing extreme fatigue, paleness, and shortness of breath.

• Unexplained Weight Loss: Rapidly dropping weight without changes to diet or exercise routines.

• Incomplete Evacuation: A persistent sensation of needing to pass a stool even right after opening the bowels (tenesmus), often associated with lower colon tumours.

6. Diagnosis and Screening Protocols

When colon cancer is suspected or flagged via a positive home FIT kit, a strict diagnostic sequence is initiated:

• Colonoscopy: The gold-standard tool. A flexible tube fitted with a camera is guided through the large intestine, allowing clinicians to inspect the mucosa and remove tissue samples.

• Staging Scans: If a biopsy confirms malignancy, a contrast-enhanced CT scan of the chest, abdomen, and pelvis is ordered alongside a pelvic MRI to check for structural invasion.

• Genomic Biomarker Profiling: Standard 2026 protocol dictates that biopsy tissue undergoes next-generation sequencing to check for RAS mutations (KRAS/NRAS), BRAF mutations, and MSI status to determine drug eligibility.

7. Staging and Classification

Staging dictates whether treatment intent will focus on complete eradication or systemic management:

• Stage 1 & 2: The cancer is confined to the inner mucosal layers or muscular wall of the colon, without breaching the outer lining or entering lymph nodes.

• Stage 3 (Locally Advanced): The tumour has spread to nearby regional lymph nodes in the mesentery, but has not migrated to distant organs.

• Stage 4 (Metastatic): Malignant cells have broken away via the bloodstream or lymphatic network to colonise distant organs—most commonly the liver, lungs, or peritoneal cavity.

8. Treatment (2026 Standards)

Treatment pathways are tailored based on the exact anatomical location, stage, and genetic profile of the tumour:

• Surgical Resection: The primary cure for localised disease. Surgeons perform a colectomy (removing the cancerous section), typically utilising minimally invasive laparoscopic or robotic surgery.

• Frontline Immunotherapy: For patients with MSI-H advanced colon cancer, 2026 guidelines favour starting directly with dual immune checkpoint inhibitors (such as Nivolumab plus Ipilimumab) over traditional chemotherapy.

• Adjuvant Chemotherapy: For Stage 3 and high-risk Stage 2 patients, combination chemotherapy regimens (such as FOLFOX or CAPOX) are administered post-surgery to destroy micro-metastatic cells.

• Targeted Biologicals: For metastatic MSS disease, treatment combines standard chemotherapy with targeted monoclonal antibodies (like Cetuximab for RAS wild-type tumours, or Bevacizumab to cut off tumour blood supply).

9. Complications and Outlook

While therapeutic management has improved outcomes, colon cancer presents serious clinical challenges:

• Survival Rates: Caught at Stage 1, the 5-year survival rate is above 90%. However, because many patients are still diagnosed late, the overall 5-year survival rate is around 60%, with 10-year survival is roughly 54%.

• Bowel Obstruction: A growing tumour can completely block the intestinal lumen, causing severe pain, vomiting, and a risk of bowel perforation requiring emergency surgery.

• Metastatic Vulnerability: The portal venous system drains directly from the colon to the liver, making the liver the most common site for secondary tumours, which often require complex secondary resections.

10. When to See a Doctor

If you experience blood in your stool, a persistent change in bowel habits lasting longer than three weeks, or unexplained abdominal pain, contact your GP for a clinical assessment and a FIT kit.

Top Tip: Never ignore symptoms or a positive home screening kit because you assume it is “just haemorrhoids” or irritable bowel syndrome (IBS). A new change in bowel habits in someone over 50 requires objective investigation. Completing the NHS home FIT kit when it arrives can literally save your life.

Summary

Colon cancer remains highly prevalent, yet it is one of the most preventable and treatable malignancies if caught early. Addressing modifiable risks through balanced dietary habits, reducing processed meat, and increasing physical activity form the bedrock of prevention.

For patients navigating the landscape in 2026, the transition toward personalised, biomarker-driven oncology—particularly immunotherapies for specific genetic subtypes and robotic-assisted surgeries—continues to optimise survival rates and preserve long-term quality of life.